Not everyone who carries a genetic risk factor for Alzheimer's disease will develop it. And not everyone who develops Alzheimer's carries a known risk variant. This is one of the most important — and most misunderstood — aspects of the genetics of cognitive aging.
But genetic research has made significant progress in identifying who may be at elevated risk, and when. One gene in particular sits at the center of that research: TOMM40.
What Is TOMM40?
TOMM40 — short for Translocase of Outer Mitochondrial Membrane 40 — is a gene involved in mitochondrial function. A specific variation within TOMM40, involving the length of a poly-T repeat sequence, has been associated with the age at which individuals with a common Alzheimer's risk gene (APOE ε3) may develop memory decline.
In simple terms: certain variants of TOMM40 appear to be associated with earlier onset of cognitive symptoms in people who are already at some genetic risk.
TOMM40 and the TOMMORROW Study
This relationship between TOMM40 variants and cognitive aging was central to the TOMMORROW trial. Researchers used TOMM40 genotyping — alongside APOE status — to enroll participants with the highest statistical likelihood of developing mild cognitive impairment within five years.
This made TOMMORROW one of the first large-scale trials to use genetic risk stratification to design a prevention study in cognitively healthy adults. Even though the trial's primary endpoint was not met, the biomarker methodology it validated continues to inform clinical research worldwide.
What Genetics Can — and Cannot — Tell You
It's important to approach genetic risk information with both curiosity and caution. Having a risk variant does not mean you will develop Alzheimer's. Not having one does not mean you are protected.
Alzheimer's disease is complex, influenced by genetics, lifestyle, cardiovascular health, sleep, and factors researchers are still working to understand. Genetic testing can be a useful tool for researchers designing prevention trials, but for individuals, it should always be interpreted in the context of a full clinical picture — and in consultation with a qualified healthcare provider.
The Promise of Precision Prevention
What genetic research like TOMMORROW's has made possible is a future of precision prevention — tailoring interventions to the individuals most likely to benefit, at the moment they're most likely to benefit from them. That future is not yet fully realized. But the science that will get us there is advancing, and understanding your own risk landscape is part of navigating it with clarity.
